ACRO Statement Supporting the Patient-Centered Outcomes Research Act of 2009
WASHINGTON-The following is the statement of Doug Peddicord, PhD, Executive Director of the Association of Clinical Research Organizations (ACRO), on S. 1213 the “Patient-Centered Outcomes Research Act.”
The Association of Clinical Research Organizations (ACRO) is pleased to lend its support to the “Patient-Centered Outcomes Research Act” introduced by Senator Max Baucus (D-MT) and Senator Kent Conrad (D-ND). ACRO also supports the related House bill, H.R. 2502, introduced by Rep. Kurt Schrader (D-OR).
In addition to protecting patient access to quality health care and encouraging continued innovation in drug development, S. 1213 and H.R. 2502 address a major shortcoming of the comparative effectiveness research provisions of the “American Recovery and Reinvestment Act” (ARRA) by creating a real, independent public-private structure to fund, prioritize, design, analyze and report on this important research.
ACRO remains concerned that certain privacy provisions of ARRA that serve to restrict access to health data will make comparative effectiveness research more difficult and expensive to conduct. As these bills move through the legislative process, we encourage Congress to remedy these unnecessary restrictions to data access so the promised benefits of comparative effectiveness research can be realized.
Further, to ensure CER funds are spent in a manner that supports sound, efficient research, ACRO believes two key criteria must be considered when awarding research projects: that priority be given to organizations that have a demonstrated ability to aggregate, synthesize and analyze large amounts of data from disparate sources; and that the organizations conducting the research have the proven ability to access a wide variety of research sites and to reach diverse patient populations for the purpose of clinical research.
About ACRO
The Association of Clinical Research Organizations (ACRO) is the professional organization of companies whose focus is clinical research. The association provides an active voice for the CRO industry, which provides specialized services that are integral to the development of drugs, biologics and medical devices. ACRO helps its members improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 70,000 professionals worldwide. For more information, please visit www.acrohealth.org.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
